Regimens Set to Overtake Monotherapies in Total Immuno-Oncology (IO) Sales

As evidenced at ASCO’s Annual Meeting, the use of combinations of novel therapies with established regimens is critical to expanding into established lines or other indications, especially as a drug’s market matures and it chases harder to reach patient pools.

But what effect does this have on costs? IQVIA ran an analysis using IQVIA’s Oncology Link, Regimen Link, and Forecast Link modules to compare checkpoint inhibitor sales to those of the constituent oncology drugs within a regimen. Explore what was uncovered, in your free article.